Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital/ University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by S C Clement in
Google Scholar
PubMed
Search for other papers by W E Visser in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by C A Lebbink in
Google Scholar
PubMed
Search for other papers by D Albano in
Google Scholar
PubMed
Search for other papers by H L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by A Czarniecka in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Search for other papers by R P Dias in
Google Scholar
PubMed
Search for other papers by M P Dierselhuis in
Google Scholar
PubMed
Search for other papers by I Dzivite-Krisane in
Google Scholar
PubMed
Search for other papers by R Elisei in
Google Scholar
PubMed
Search for other papers by A Garcia-Burillo in
Google Scholar
PubMed
Search for other papers by L Izatt in
Google Scholar
PubMed
Search for other papers by C Kanaka-Gantenbein in
Google Scholar
PubMed
Search for other papers by H Krude in
Google Scholar
PubMed
Search for other papers by L Lamartina in
Google Scholar
PubMed
Search for other papers by K Lorenz in
Google Scholar
PubMed
Search for other papers by M Luster in
Google Scholar
PubMed
Search for other papers by R Navardauskaitė in
Google Scholar
PubMed
Search for other papers by M Negre Busó in
Google Scholar
PubMed
Search for other papers by K Newbold in
Google Scholar
PubMed
Search for other papers by R P Peeters in
Google Scholar
PubMed
Search for other papers by G Pellegriti in
Google Scholar
PubMed
Search for other papers by A Piccardo in
Google Scholar
PubMed
Search for other papers by A L Priego in
Google Scholar
PubMed
Search for other papers by A Redlich in
Google Scholar
PubMed
Search for other papers by L de Sanctis in
Google Scholar
PubMed
Search for other papers by M Sobrinho-Simões in
Google Scholar
PubMed
Search for other papers by A S P van Trotsenburg in
Google Scholar
PubMed
Search for other papers by F A Verburg in
Google Scholar
PubMed
Search for other papers by M Vriens in
Google Scholar
PubMed
Search for other papers by T P Links in
Google Scholar
PubMed
Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK
Office for Rare Conditions, University of Glasgow, Glasgow, UK
Search for other papers by S F Ahmed in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by H M van Santen in
Google Scholar
PubMed
Background Pediatric differentiated thyroid carcinoma (DTC) is a rare disease, although it is the most frequent endocrine malignancy in children, representing 2–4% of all pediatric malignancies. According to the Surveillance, Epidemiology, and
Search for other papers by Danuta Gąsior-Perczak in
Google Scholar
PubMed
Search for other papers by Iwona Pałyga in
Google Scholar
PubMed
Search for other papers by Monika Szymonek in
Google Scholar
PubMed
Search for other papers by Artur Kowalik in
Google Scholar
PubMed
Search for other papers by Agnieszka Walczyk in
Google Scholar
PubMed
Search for other papers by Janusz Kopczyński in
Google Scholar
PubMed
Search for other papers by Katarzyna Lizis-Kolus in
Google Scholar
PubMed
Search for other papers by Anna Słuszniak in
Google Scholar
PubMed
Search for other papers by Janusz Słuszniak in
Google Scholar
PubMed
Search for other papers by Tomasz Łopatyński in
Google Scholar
PubMed
Search for other papers by Ryszard Mężyk in
Google Scholar
PubMed
The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland
Search for other papers by Stanisław Góźdź in
Google Scholar
PubMed
The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland
Search for other papers by Aldona Kowalska in
Google Scholar
PubMed
Introduction Increased access to imaging techniques and fine-needle aspiration cytology (FNAC) has resulted in an increase in the rate of detection of differentiated thyroid cancer (DTC) in recent years ( 1 , 2 , 3 , 4 ). The increase in
Search for other papers by Maria Luisa Garo in
Google Scholar
PubMed
Search for other papers by Désirée Deandreis in
Google Scholar
PubMed
Search for other papers by Alfredo Campennì in
Google Scholar
PubMed
Search for other papers by Alexis Vrachimis in
Google Scholar
PubMed
Search for other papers by Petra Petranovic Ovcaricek in
Google Scholar
PubMed
Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland
Search for other papers by Luca Giovanella in
Google Scholar
PubMed
Introduction Differentiated thyroid cancer (DTC) accounts for 90% of all thyroid cancers and is increasing threefold every decade ( 1 ) so that by 2040 it will be the fourth most common malignancy in the group aged 20–49 years ( 2 ). Papillary
Search for other papers by Alexander Heinzel in
Google Scholar
PubMed
Search for other papers by Dirk Müller in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Emma Children’s Hospital, Amsterdam UMC, Department of Pediatrics, Amsterdam, The Netherlands
Search for other papers by Sarah C Clement in
Google Scholar
PubMed
Search for other papers by Arthur B Schneider in
Google Scholar
PubMed
University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, Germany
Search for other papers by Frederik A Verburg in
Google Scholar
PubMed
Introduction Childhood cancer survivors (CCS) who received radiation therapy to the cervical region (cranial/ cranio-spinal or chest) are at increased risk of developing differentiated thyroid cancer (DTC) among other malignancies. Long
Search for other papers by Hyunjae Lee in
Google Scholar
PubMed
Search for other papers by Tae-Shin Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Ja-Yoon Gu in
Google Scholar
PubMed
Search for other papers by Mi Ran Yu in
Google Scholar
PubMed
Search for other papers by Seung-Eun Lee in
Google Scholar
PubMed
Search for other papers by Eun Sook Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Hyun Kyung Kim in
Google Scholar
PubMed
Introduction Differentiated thyroid cancer (DTC) is the most commonly diagnosed endocrine malignancy ( 1 ) and the risk of its recurrence varies from patient to patient, ranging from less than 5% to more than 20% ( 2 ). Efforts have been made
Division of General Medicine, Istituto Auxologico Italiano, IRCCS, S. Giuseppe Hospital, Piancavallo di Oggebbio (VB), Italy
Search for other papers by Chiara Mele in
Google Scholar
PubMed
Search for other papers by Maria Teresa Samà in
Google Scholar
PubMed
Search for other papers by Alessandro Angelo Bisoffi in
Google Scholar
PubMed
Search for other papers by Marina Caputo in
Google Scholar
PubMed
Search for other papers by Valentina Bullara in
Google Scholar
PubMed
Search for other papers by Stefania Mai in
Google Scholar
PubMed
Search for other papers by Gillian Elisabeth Walker in
Google Scholar
PubMed
Search for other papers by Flavia Prodam in
Google Scholar
PubMed
Division of General Medicine, Istituto Auxologico Italiano, IRCCS, S. Giuseppe Hospital, Piancavallo di Oggebbio (VB), Italy
Search for other papers by Paolo Marzullo in
Google Scholar
PubMed
Search for other papers by Gianluca Aimaretti in
Google Scholar
PubMed
Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy
Search for other papers by Loredana Pagano in
Google Scholar
PubMed
Introduction The incidence rates of differentiated thyroid cancer (DTC) have been rising in many countries over the last few decades ( 1 , 2 ) along with a parallel increase in obesity and metabolic disorders ( 3 ). Even if the growing
Grup de Mutagènesi, CIBER Epidemiología y Salud Pública, Servei de Medicina Nuclear, Unidad de Endocrinología, Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain
Search for other papers by Susana Pastor in
Google Scholar
PubMed
Search for other papers by Abdelmounaim Akdi in
Google Scholar
PubMed
Search for other papers by Eddy R González in
Google Scholar
PubMed
Search for other papers by Juan Castell in
Google Scholar
PubMed
Search for other papers by Josefina Biarnés in
Google Scholar
PubMed
Grup de Mutagènesi, CIBER Epidemiología y Salud Pública, Servei de Medicina Nuclear, Unidad de Endocrinología, Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain
Search for other papers by Ricard Marcos in
Google Scholar
PubMed
Grup de Mutagènesi, CIBER Epidemiología y Salud Pública, Servei de Medicina Nuclear, Unidad de Endocrinología, Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain
Search for other papers by Antonia Velázquez in
Google Scholar
PubMed
Introduction Thyroid cancer is of special concern in endocrinology practice, accounting for more than 90% of all endocrine cancers. Moreover, its incidence is increasing in developed countries (1, 2) . Differentiated thyroid carcinoma (DTC
Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland
Search for other papers by Luca Giovanella in
Google Scholar
PubMed
Search for other papers by Maria Luisa Garo in
Google Scholar
PubMed
Search for other papers by Domenico Albano in
Google Scholar
PubMed
Search for other papers by Rainer Görges in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
Search for other papers by Luca Ceriani in
Google Scholar
PubMed
Introduction In many cases, differentiated thyroid carcinoma (DTC) has an indolent course and a generally favorable prognosis. However, recurrences may occur in up to 20% of DTC patients, with 10% of them having a fatal outcome ( 1 ). Serum
Search for other papers by Eugenie S Lim in
Google Scholar
PubMed
Search for other papers by Shanty G Shah in
Google Scholar
PubMed
Search for other papers by Mona Waterhouse in
Google Scholar
PubMed
Barts and the London School of Medicine and Dentistry, QMUL, London, UK
Search for other papers by Scott Akker in
Google Scholar
PubMed
Barts and the London School of Medicine and Dentistry, QMUL, London, UK
Search for other papers by William Drake in
Google Scholar
PubMed
Barts and the London School of Medicine and Dentistry, QMUL, London, UK
Search for other papers by Nick Plowman in
Google Scholar
PubMed
Barts and the London School of Medicine and Dentistry, QMUL, London, UK
Search for other papers by Daniel M Berney in
Google Scholar
PubMed
Search for other papers by Polly Richards in
Google Scholar
PubMed
Search for other papers by Ashok Adams in
Google Scholar
PubMed
Search for other papers by Ewa Nowosinska in
Google Scholar
PubMed
Search for other papers by Carmel Brennan in
Google Scholar
PubMed
Barts and the London School of Medicine and Dentistry, QMUL, London, UK
Search for other papers by Maralyn Druce in
Google Scholar
PubMed
Introduction Differentiated thyroid cancer (DTC) is the most frequently occurring endocrine cancer and its incidence has been increasing steadily in men and women over the last few decades ( 1 , 2 , 3 ). DTC includes papillary thyroid cancer
Structural and Functional Biology Program, Universidade Federal de São Paulo, São Paulo, Brazil
Search for other papers by Erika Urbano Lima in
Google Scholar
PubMed
Structural and Functional Biology Program, Universidade Federal de São Paulo, São Paulo, Brazil
Search for other papers by Ileana G S Rubio in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Joaquim Custodio Da Silva in
Google Scholar
PubMed
Search for other papers by Ana Luiza Galrão in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Danielle Pêssoa in
Google Scholar
PubMed
Search for other papers by Taise Cerqueira Oliveira in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Fabiane Carrijo in
Google Scholar
PubMed
Search for other papers by Igor Silva Campos in
Google Scholar
PubMed
Department of Anatomic Pathology & Legal Medicine, Bahia Federal Medical School, Federal University of Bahia, Salvador, Brazil
Search for other papers by Luciano Fonseca Espinheira in
Google Scholar
PubMed
Search for other papers by Luiz Jose Sampaio in
Google Scholar
PubMed
Search for other papers by Claudio Rogerio Lima in
Google Scholar
PubMed
Division of Genetics, Department of Morphology and Genetics, Genetic Basis of Thyroid Tumors Laboratory, Paulista School of Medicine, Universidade Federal de São Paulo, São Paulo, Brazil
Search for other papers by Janete Maria Cerutti in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Helton Estrela Ramos in
Google Scholar
PubMed
Introduction Differentiated thyroid cancer (DTC) has continued to increase over the past several decades, likely due to enhanced detection ( 1 , 2 ). Cancer research, in general, has benefited greatly from many of the new scientific